BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20101404)

  • 1. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
    Jain D; Patel N; Shelton M; Basu A; Roque R; Siede W
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):945-52. PubMed ID: 20101404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rad5 template switch pathway of DNA damage tolerance determines synergism between cisplatin and NSC109268 in Saccharomyces cerevisiae.
    Jain D; Siede W
    PLoS One; 2013; 8(10):e77666. PubMed ID: 24130896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells].
    Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY
    Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
    Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
    Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug resistant mechanisms of platinum derivatives in a human cisplatin resistant ovarian cancer cell line].
    Nishiya I; Yoshizumi N; Fujiwara J; Kagabu T
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2871-81. PubMed ID: 3178236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tannic acid, an inhibitor of poly(ADP-ribose) glycohydrolase, sensitizes ovarian carcinoma cells to cisplatin.
    Sun Y; Zhang T; Wang B; Li H; Li P
    Anticancer Drugs; 2012 Oct; 23(9):979-90. PubMed ID: 22785358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.
    Bhuyan BK; Smith KS; Adams EG; Petzold GL; McGovren JP
    Cancer Res; 1992 Oct; 52(20):5687-92. PubMed ID: 1394193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.
    Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
    Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
    Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
    Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
    Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
    J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.